A20 (catalytic domain) (human), (recombinant) (untagged)



BML-UW1015-0100	100 µg	214.00 USD

Product Specification

Alternative Name:	Tumor necrosis factor alpha-induced protein 3 , TNAP3, TNFAIP3, OTU domain-containing protein 7C, Putative DNA-binding protein A20, Zinc finger protein A20

Concentration:	2mg/ml

MW:	~43kDa

Purity:	≥80% (SDS-PAGE)

Formulation:	Liquid. In 25mM TRIS-HCl, pH 8.5, containing 200mM sodium chloride, 1mM EDTA and 5mM DTT.

Source/Host:	Produced in E. coli.

Long Term Storage:	-80°C

Use/Stability:	Stable for at least 1 year after receipt when stored at -80°C.

Handling:	After opening, prepare aliquots and store at -80°C. Avoid freeze/thaw cycles.

Miscellaneous/General:	For use in deubiquitinylation assays. The NF-κB (nuclear factor κB) regulator A20 antagonizes IKK [IκB (inhibitor of κB) kinase] activation by modulating Lys⁶³-linked polyubiquitinylation of cytokine-receptor-associated factors including TRAF2/6, RIP1 and the IKK subunit NEMO. A20 possess both deubiquitinylating and ubiquitin E3 ligase activities, through its N-terminal OTU (ovarian tumour) and seven A20-like ZF (zinc finger) domains respectively and acts by disassembling Lys⁶³-linked polyubiquitin chains from TRAF2/6 and RIP1, subsequently replacing them with Lys⁴⁸-linked polyubiquitin. This dual action not only antagonizes downstream signalling, by indirectly stabilizing IκB, but also targets the substrates for proteasomal degradation.

Background / Technical Information:	UniProt ID: P21580 Tumor necrosis factor alpha-induced protein 3 (human) The isolated A20 OTU catalytic domain (CD) has been shown to exhibit a preference for Lys⁴⁸-linked tetraubiquitin in vitro suggesting that additional specificity factors might be required for the physiological function of A20 in cells. Note: A20CD must be pre-incubated with 10mM DTT at room temperature for 15 minutes to activate the enzyme prior to running activity assays.